Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338933 · ClinicalTrials.gov registry record
Neurobiology of Alcohol and Nicotine Co-Addiction
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 109
- Enrollment target
NCT03338933: Completed study, sponsored by VA Office of Research and Development.
NCT03338933 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03338933 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
This proposal addresses the critical absence of information about the neurobiology of recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users.
Primary Outcome
The DSN-back is a cognitive task used to assess working memory and attention. Participants view a sequence of letters presented on a screen, flanked by either drug-related or neutral images, and are instructed to identify matches occurring N steps earlier. Neural activation during high working memory demand condition (2-back) relative to the low working memory condition (0-back) was investigated. Inconsistent activation patterns across regions may indicate impaired neural processing in regions c
Interventions
- BEHAVIORAL magnetic resonance imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2023-01-03 |
What the finished NCT03338933 record still lists
NCT03338933 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which magnetic resonance imaging (MRI) is the first listed.
NCT03338933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03338933 about?
NCT03338933 is a clinical study titled "Neurobiology of Alcohol and Nicotine Co-Addiction". This proposal addresses the critical absence of information about the neurobiology of recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users.
What is the current status of trial NCT03338933?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2018-02-08. Estimated completion is 2023-01-03.
What interventions are being tested in trial NCT03338933?
The interventions under investigation include: magnetic resonance imaging (MRI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03338933?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI